Commure, a $7 billion health software company, has terminated its customer referral program that offered payments for promoting its AI tools to new medical clinics. The decision follows a STAT investigation into the company's referral arrangements, which were disclosed in internal emails from Chief Legal Officer Dan Brian.
Both the U.S. and U.K. health systems prioritize clinical interventions over community-based prevention, despite rising chronic illness and loneliness. A shift toward social infrastructure and community empowerment could reduce strain on hospitals and improve public health outcomes.
The U.S. FDA has approved Zenbexus, Bristol Myers Squibb’s oral treatment for advanced multiple myeloma, introducing a new class of blood cancer drugs known as CELMoDs. Meanwhile, a U.S. appeals court revived a $6.7 billion lawsuit accusing Bristol Myers of delaying regulatory approvals for three drugs post-Celgene acquisition.